Fentiazac

Fentiazac is a thiazole-based nonsteroidal anti-inflammatory drug (NSAID) developed for use in joint and muscular pain.^[1] Like most other NSAIDs, it acts through inhibition of prostaglandin synthesis, via non-selective inhibition of both COX-1 and COX-2. First described in 1974, it was synthesized using the Hantzsch thiazole synthesis.^[2]

Fentiazac

Clinical data
Trade names	Norvedan
AHFS/Drugs.com	International Drug Names
ATC code	M02AA14 (WHO)
Identifiers
IUPAC name 2-[4-(4-chlorophenyl)-2-phenyl-1,3-thiazol-5-yl]acetic acid
CAS Number	18046-21-4 N
PubChem CID	28871
ChemSpider	26854 N
UNII	0YHF6E6NLS
KEGG	D01975 Y
ChEMBL	ChEMBL589092 N
CompTox Dashboard (EPA)	DTXSID8023050
ECHA InfoCard	100.038.129
Chemical and physical data
Formula	C17H12ClNO2S
Molar mass	329.80 g·mol−1
3D model (JSmol)	Interactive image
Melting point	162–163 °C (324–325 °F)
SMILES c1ccc(cc1)c2nc(c(s2)CC(=O)O)c3ccc(cc3)Cl
InChI InChI=1S/C17H12ClNO2S/c18-13-8-6-11(7-9-13)16-14(10-15(20)21)22-17(19-16)12-4-2-1-3-5-12/h1-9H,10H2,(H,20,21) N Key:JIEKMACRVQTPRC-UHFFFAOYSA-N N
NY (what is this?)  (verify)

Fentiazac was marketed under the trade-name Norvedan (among others), but its market status is currently unknown and assumed to be discontinued.^[3]

See also

• Fenclozic acid